Zacks: Halyard Health Receives Average Rating of "Buy" from Analysts (NYSE:HYH)

Shares of Halyard Health (NYSE:HYH) have been given a consensus broker rating score of 2.33 (Buy) from the four analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong sell recommendation, one has issued a hold recommendation and two have assigned a strong buy recommendation to the company.

Brokers have set a one year consensus price objective of $33.50 for the company and are expecting that the company will post $0.52 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Halyard Health an industry rank of 66 out of 265 based on the ratings given to related companies.

Halyard Health (NYSE:HYH) opened at 29.49 on Thursday. The stock’s market capitalization is $1.37 billion. Halyard Health has a 52-week low of $26.58 and a 52-week high of $50.92. The firm’s 50-day moving average is $29.35 and its 200-day moving average is $36.28.

Halyard Health (NYSE:HYH) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported $0.52 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.47 by $0.05. The business earned $390 million during the quarter, compared to analyst estimates of $388 million. The firm’s revenue for the quarter was down 4.5% compared to the same quarter last year. Analysts predict that Halyard Health will post $2.07 earnings per share for the current year.

In other news, CFO Steven E. Voskuil bought 1,000 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was bought at an average price of $30.00 per share, for a total transaction of $30,000.00. Following the transaction, the chief financial officer now owns 28,729 shares in the company, valued at $861,870. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Robert E. Abernathy bought 10,000 shares of the firm’s stock in a transaction dated Friday, September 4th. The stock was purchased at an average price of $31.06 per share, with a total value of $310,600.00. Following the transaction, the chief executive officer now owns 80,043 shares in the company, valued at approximately $2,486,135.58. The disclosure for this purchase can be found here.

HYH has been the subject of a number of research analyst reports. JMP Securities reiterated a “buy” rating on shares of Halyard Health in a research note on Wednesday, August 5th. Deutsche Bank initiated coverage on Halyard Health in a research note on Friday, September 11th. They set a “buy” rating and a $40.00 price target for the company. Zacks upgraded Halyard Health from a “sell” rating to a “hold” rating in a research report on Thursday, November 5th. Raymond James assumed coverage on Halyard Health in a report on Tuesday, July 21st. They issued a “market perform” rating on the stock. Finally, Morgan Stanley lowered Halyard Health from an “equal weight” rating to an “underweight” rating and set a $27.00 price objective on the stock. in a research note on Monday, October 12th.

Halyard Health, Inc. seeks to advance health and health care by preventing disease, eliminating pain and accelerating recovery. The Company has two business segments: Surgical and Infection Prevention (NYSE:HYH) and Medical Devices. The S&IP company of the Company’s provides alternatives and health care supplies that target the prevention of health care associated diseases. S&IP’s product portfolio includes medical exam gloves, surgical drapes and gowns, facial protection, protective attire and sterilization wrap. Medical Devices segment supplies a portfolio of product offerings, including post-operative pain management solutions, minimally invasive interventional (or long-term) pain treatments, closed airway suction systems and enteral feeding tubes, focused on pain management and respiratory and digestive health.

To get a free copy of the research report on Halyard Health (HYH), click here. For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Halyard Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Halyard Health and related companies with MarketBeat.com’s FREE daily email newsletter.

<!– –>

Zacks: Halyard Health Receives Average Rating of "Buy" from Analysts (NYSE:HYH)